Amgen announces phase 3 Sjögren's results: what it means for Amgen stock
Published on 10/17/2026 at 10:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults and upcoming session
- On September 22, 2026, Amgen announced positive phase 3 results for dazodalibep.
- The next Xetra session is scheduled for October 19, 2026.
- Amgen's investor page labels its earnings presentation Q2 2026.
Amgen announced positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease on September 22, 2026, according to Amgen investor relations.
Market context: Market report S&P 500.
Weekend trading
The next Xetra session is scheduled for October 19, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.
Amgen's latest development
The investor-relations page lists the September 22, 2026 announcement as a news release concerning positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease. The page also identifies Amgen's Q2 2026 earnings conference call and related investor presentation materials. Both items are listed by Amgen investor relations.
Next Xetra session
The next scheduled Xetra session falls on October 19, 2026. The dated company materials reviewed here include the Q2 2026 earnings presentation and the September 22, 2026 dazodalibep announcement.
